LifeVantage (LFVN) Stock Overview
Engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, pre and pro-biotics and skin and hair care products internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
LFVN Community Fair Values
Create NarrativeSee what 46 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
LifeVantage Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.43 |
| 52 Week High | US$15.00 |
| 52 Week Low | US$3.90 |
| Beta | 0.39 |
| 1 Month Change | 27.76% |
| 3 Month Change | 1.31% |
| 1 Year Change | -53.90% |
| 3 Year Change | 41.04% |
| 5 Year Change | -27.50% |
| Change since IPO | -77.84% |
Recent News & Updates
LFVN: Share Repurchases And Reset Expectations Will Support Future Upside Potential
Analysts have trimmed their price target on LifeVantage by $7, reflecting updated views on the company’s fair value and earnings power following recent research. Analyst Commentary Analysts cutting the target price by $7 signals a reset in expectations around what they see as a fair value for LifeVantage, given recent research on the company’s earnings power and execution risks.LFVN: Share Repurchases And Portugal Expansion Will Support Future Upside Potential
Analysts have reduced their price target on LifeVantage by $7, citing updated assumptions around discount rates, revenue trends, profit margins, and expected future P/E multiples. Analyst Commentary Analysts link the lower price target to updated views on discount rates, revenue trends, profit margins, and expected future P/E multiples, which together affect how much investors may be willing to pay for LifeVantage shares.LFVN: Share Repurchases And Margin Discipline Will Support Future Upside Potential
Analysts have reduced their price target on LifeVantage by $7, citing updated assumptions around discount rates, long term revenue trends, profit margins, and future P/E expectations. Analyst Commentary Analysts cutting the price target by $7 are updating their framework for discount rates, long term revenue trends, profit margins, and future P/E expectations.Recent updates
LFVN: Share Repurchases And Reset Expectations Will Support Future Upside Potential
Analysts have trimmed their price target on LifeVantage by $7, reflecting updated views on the company’s fair value and earnings power following recent research. Analyst Commentary Analysts cutting the target price by $7 signals a reset in expectations around what they see as a fair value for LifeVantage, given recent research on the company’s earnings power and execution risks.LFVN: Share Repurchases And Portugal Expansion Will Support Future Upside Potential
Analysts have reduced their price target on LifeVantage by $7, citing updated assumptions around discount rates, revenue trends, profit margins, and expected future P/E multiples. Analyst Commentary Analysts link the lower price target to updated views on discount rates, revenue trends, profit margins, and expected future P/E multiples, which together affect how much investors may be willing to pay for LifeVantage shares.LFVN: Share Repurchases And Margin Discipline Will Support Future Upside Potential
Analysts have reduced their price target on LifeVantage by $7, citing updated assumptions around discount rates, long term revenue trends, profit margins, and future P/E expectations. Analyst Commentary Analysts cutting the price target by $7 are updating their framework for discount rates, long term revenue trends, profit margins, and future P/E expectations.LFVN: Share Repurchases And Stable Margins Will Support Future Upside Potential
Analysts have trimmed their $7.00 price target on LifeVantage, citing updated fair value, discount rate, revenue, margin, and future P/E assumptions that now point to a more measured risk and return profile for the stock. Analyst Commentary Analysts cutting their $7.00 price target are largely reacting to updated views on fair value, discount rate, revenue, margins, and future P/E assumptions, which together frame a more balanced outlook for LifeVantage.LFVN: Buybacks And Margin Improvement Will Support Future Upside Potential
Narrative Update on LifeVantage Analysts have lowered their price target on LifeVantage by $7, citing updated assumptions for the discount rate, revenue trajectory, profit margin and future P/E, which together indicate a more cautious valuation framework. Analyst Commentary Analysts describe the lower price target as a reset of expectations rather than a change in the core story, anchoring their work in updated views on discount rate, revenue trajectory, profit margin and future P/E.LFVN: Higher Future P/E And Buybacks Will Support Confident Upside Potential
Analysts have reduced their price target on LifeVantage from $14.50 to $8.00, citing updated assumptions for revenue trends, profit margins, and a slightly adjusted discount rate, even as they apply a somewhat higher future P/E multiple. Analyst Commentary Analysts cutting the price target to $8.00 are recalibrating how they see LifeVantage balancing execution risk with potential upside in its valuation.Investors Give LifeVantage Corporation (NASDAQ:LFVN) Shares A 26% Hiding
Feb 06
LFVN: Gut Health Research Progress Will Support Confident Upside Potential
Analysts are keeping their price target for LifeVantage steady at US$14.50, indicating only very small adjustments in their discount rate and long term assumptions such as revenue growth, profit margin and future P/E that do not materially change their overall view. What's in the News LifeVantage announced new in vitro study results for its proprietary P84 formula, showing strong biological activity in cellular pathways linked to gut regulation, repair, and restoration across four gut cell types (Key Developments).LFVN: Gut Study Advances And Guidance Confidence Will Support Future Upside Potential
Analysts have kept their price target for LifeVantage unchanged at $14.50, reflecting only minor tweaks to assumptions around discount rate, revenue growth, profit margin and future P/E, rather than a shift in their overall view of the stock. What's in the News LifeVantage reported new in vitro study results for its proprietary P84 formula, showing strong biological activity in cellular pathways tied to gut regulation, repair, and restoration across four gut cell types, with all 14 analyzed peptides and proteins moving in the intended direction in a controlled, third party study (Key Developments).LFVN: Gut Study Progress Will Drive Future Upside Potential
Analysts have slightly adjusted their price target for LifeVantage to $14.50, reflecting small tweaks to assumptions around the discount rate, long term revenue growth, profit margin, and future P/E used in their valuation models. What's in the News LifeVantage reported new in vitro study results for its proprietary P84 formula, with all 14 analyzed gut-related peptides and proteins moving in the desired direction in a controlled, third-party study across four gut cell types (Key Developments).LFVN: Future Gut Health Research And Buybacks Will Drive Upside
Analysts have modestly raised their price target on LifeVantage to 14.50 dollars from 14.50 dollars, citing largely unchanged expectations for fair value, discount rate, revenue growth, profit margins, and future valuation multiples that together reinforce a stable outlook for the shares. What's in the News New in vitro study of LifeVantage's P84 gut health formula showed strong biological activity across 14 key gut peptides and proteins, with several biomarkers increasing well above the 20 to 30 percent threshold typically considered meaningful in controlled cellular research (Key Developments) Key P84 results included a 1,087 percent increase in gastrin releasing peptide, a 116 percent increase in trefoil factor 3 for gut lining repair, and a 100 percent increase in vasoactive intestinal peptide that helps calm overactive areas of the gut (Key Developments) LifeVantage plans next phase research using mRNA sequencing to study P84 in combination with its Protandim Nrf2 Synergizer and MindBody GLP 1 System formulas, deepening the scientific backing for its gut and cellular activation portfolio (Key Developments) LifeVantage reported it has repurchased a cumulative 5,068,960 shares, or 37.65 percent of its outstanding stock, for 43.27 million dollars under a buyback program initiated in 2017, including 44,364 shares in the most recent quarter (Key Developments) The company reiterated fiscal 2026 guidance, expecting full year revenue between 225 million and 240 million dollars and forecasting second half revenue to exceed the first half, supported by MindBody product seasonality and the LoveBiome acquisition (Key Developments) Valuation Changes Fair Value Estimate: unchanged at 14.50 dollars per share, indicating no material shift in the intrinsic value assessment.LFVN: Future Index Inclusion Will Drive Upside Potential
Analysts have modestly raised their price target on LifeVantage to approximately $14.50 per share, reflecting slightly updated assumptions for discount rates, long term revenue growth, and profitability, while maintaining a broadly unchanged fair value outlook. What's in the News New in vitro study of LifeVantage’s proprietary P84 gut health formula showed strong biological activity across 14 key gut peptides and proteins, with several markers, including GRP, TFF3, VIP, and OXM, demonstrating notably large increases in levels, supporting the scientific rationale behind the product portfolio expansion (company study announcement).LFVN: Share Repurchases and New Index Addition Will Drive Value
LifeVantage Analyst Price Target Revised Downward Amid Softer Growth Expectations Analysts have lowered their price target for LifeVantage from $18.00 to $14.50. They cite reduced projections for revenue growth and profit margins as key factors in their updated assessment.Lacklustre Performance Is Driving LifeVantage Corporation's (NASDAQ:LFVN) 28% Price Drop
Nov 14We Ran A Stock Scan For Earnings Growth And LifeVantage (NASDAQ:LFVN) Passed With Ease
Nov 04It's Down 25% But LifeVantage Corporation (NASDAQ:LFVN) Could Be Riskier Than It Looks
Sep 30LifeVantage (NASDAQ:LFVN) Will Pay A Dividend Of $0.045
Sep 05The LifeVantage Advantage: High Retention, High Returns
Jul 21Shareholders Can Be Confident That LifeVantage's (NASDAQ:LFVN) Earnings Are High Quality
May 13What You Can Learn From LifeVantage Corporation's (NASDAQ:LFVN) P/E After Its 26% Share Price Crash
May 02
New Initiatives Will Drive MindBody GLP-1 System's Future Success
Expansion into international markets and enhanced supply chain capacity are expected to drive significant revenue growth and stabilize future sales.LifeVantage (NASDAQ:LFVN) Will Pay A Dividend Of $0.04
Feb 09LifeVantage Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Feb 07LifeVantage: Post-Earnings Sell-Off Provides Buying Opportunity
Feb 06LifeVantage Corporation (NASDAQ:LFVN) Looks Just Right With A 33% Price Jump
Feb 05What Is LifeVantage Corporation's (NASDAQ:LFVN) Share Price Doing?
Feb 01Market Participants Recognise LifeVantage Corporation's (NASDAQ:LFVN) Earnings Pushing Shares 31% Higher
Dec 20LifeVantage (NASDAQ:LFVN) Will Be Hoping To Turn Its Returns On Capital Around
Dec 16LifeVantage's (NASDAQ:LFVN) Dividend Will Be $0.04
Nov 16LifeVantage's (NASDAQ:LFVN) Dividend Will Be $0.04
Nov 02Shareholder Returns
| LFVN | US Personal Products | US Market | |
|---|---|---|---|
| 7D | -1.5% | 0.07% | 0.9% |
| 1Y | -53.9% | -15.4% | 28.2% |
Return vs Industry: LFVN underperformed the US Personal Products industry which returned -15.5% over the past year.
Return vs Market: LFVN underperformed the US Market which returned 27.8% over the past year.
Price Volatility
| LFVN volatility | |
|---|---|
| LFVN Average Weekly Movement | 9.4% |
| Personal Products Industry Average Movement | 9.2% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: LFVN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LFVN's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 235 | Michael Beindorff | www.lifevantage.com |
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, pre and pro-biotics and skin and hair care products internationally. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; LifeVantage Daily Wellness, a dietary supplement to strengthen immune health; LifeVantage Rise AM and Reset PM System that provides the body with the right nutrients; LifeVantage D3+, a dietary supplement that provides vitamin D3 and K2, magnesium, calcium, and other trace minerals to support a balanced immune system, strong bones, and cardiovascular health; PhysIQ Fat Burn to support weight management; PhysIQ Prebiotic is a dietary supplement designed to support the good bacteria in the gut and a healthy microbiome; MindBody GLP-1 System, a dietary supplement that combines two products, MB Core and MB Enhance, which are designed to support weight management and wellness by activating GLP-1 naturally and balancing signals along the gut-brain axis; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. It also provides anti-aging skin care products, such as liquid collagen, facial cleansers, eye cream, moisturizing cream, sunscreen, perfecting lotions, and hand creams, as well as shampoos, nourishing conditioners, and scalp serums under the TrueScience brand name.
LifeVantage Corporation Fundamentals Summary
| LFVN fundamental statistics | |
|---|---|
| Market cap | US$69.53m |
| Earnings (TTM) | US$7.86m |
| Revenue (TTM) | US$210.05m |
Is LFVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LFVN income statement (TTM) | |
|---|---|
| Revenue | US$210.05m |
| Cost of Revenue | US$44.65m |
| Gross Profit | US$165.40m |
| Other Expenses | US$157.54m |
| Earnings | US$7.86m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 06, 2026
| Earnings per share (EPS) | 0.61 |
| Gross Margin | 78.75% |
| Net Profit Margin | 3.74% |
| Debt/Equity Ratio | 0% |
How did LFVN perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/04 03:16 |
| End of Day Share Price | 2026/05/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
LifeVantage Corporation is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ilya Zubkov | Freedom Broker |
| Mitchell Pinheiro | Imperial Capital |
| Ryan Meyers | Lake Street Capital Markets, LLC |